http://dspace.bsuedu.ru/handle/123456789/65285| Title: | Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19 |
| Authors: | Naletova, E.N. Naletova, O.S. Serdyuk, E.B. Naletov, S.V. Alesinsky, M.M. |
| Keywords: | medicine pharmacology arterial hypertensio COVID-19 combined antihypertensive pharmacotherapy L-arginine dihydroquercetin |
| Issue Date: | 2025 |
| Citation: | Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19 / E.N. Naletova, O.S. Naletova, E.B. Serdyuk [et al.] // Research Results in Pharmacology. - 2025. - Vol.11, №1.-P. 36-48. - Doi: 10.18413/rrpharmacology.11.469. - Refer.: p. 47-48. |
| Abstract: | The aim was to improve the effectiveness of treatment of COVID-19-treated HD patients by pharmacoepidemiologic and clinical substantiation of inclusion of L-arginine + dihydroquercetin complex in the composition of combined AHPT |
| URI: | http://dspace.bsuedu.ru/handle/123456789/65285 |
| Appears in Collections: | Vol. 11, № 1 |
| File | Description | Size | Format | |
|---|---|---|---|---|
| Naletova_Pharmacoepidemiologic_25.pdf | 313.86 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.